Soligenix awarded NIAID contract valued up to $24.7 million
Soligenix announced it has been awarded a contract valued at up to $24.7 million by NIAID. The objectives are to advance development of Soligenix's thermostabilization technology, ThermoVax™, combined with the company's ricin toxin vaccine, Rivax™, as a MCM to prevent effects of ricin exposure. September 19, 2014